Peter B. Cancelmo J.D. serves as Vice President, General Counsel, Secretary of the Company. Mr. Cancelmo has served as our vice president, general counsel and secretary since June 2019. He joined Omeros as deputy general counsel, corporate governance and securities in January 2019. Prior to joining Omeros, Mr. Cancelmo was a principal and shareholder at Garvey Schubert Barer, P.C., where he represented clients in the life sciences and other technology industries in mergers, acquisitions, strategic alliances, public and private securities offerings, and a range of other corporate, commercial and financial transactions. He served as chair of the firm’s business practice group from 2016 until his departure in December 2018. Mr. Cancelmo previously practiced corporate and transactional law at Davies, Ward, Philips and Vineberg LLP, in New York, and Choate, Hall & Stewart LLP, in Boston. Mr. Cancelmo received his J.D. from Boston University and his B.A. from Saint Michael’s College.
As the Vice President、 General Counsel、 Secretary of Omeros, the total compensation of Peter Cancelmo at Omeros is 705,959$. There are 4 executives at Omeros getting paid more, with Gregory Demopulos having the highest compensation of 4,825,130$.
Peter Cancelmo is 41, he's been the Vice President、 General Counsel、 Secretary of Omeros since 2019. There are 30 older and no younger executives at Omeros. The oldest executive at Omeros Corporation is Ray Aspiri, 83, who is the Independent Director.
Peter's mailing address filed with the SEC is 201 ELLIOTT AVENUE WEST, , SEATTLE, WA, 98119.
Over the last 15 years, insiders at Omeros have traded over 719,810$ worth of Omeros stock and bought 141,095 units worth 829,835$ . The most active insiders traders include Gregory A Md Demopulos、Marcia S. Kelbon、Daniel K Spiegelman. On average, Omeros executives and independent directors trade stock every 53 days with the average trade being worth of 97,792$. The most recent stock trade was executed by Gregory A Md Demopulos on 17 November 2023, trading 15,000 units of OMER stock currently worth 25,200$.
omeros is a seattle-based biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system.
Omeros executives and other stock owners filed with the SEC include: